Butterfly Network, Inc. (BFLY) Reports Q4 Loss, Tops Revenue Estimates

Zacks
02-28

Butterfly Network, Inc. (BFLY) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 20%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced a loss of $0.08, delivering a surprise of 20%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Butterfly Network , which belongs to the Zacks Medical Info Systems industry, posted revenues of $22.35 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.18%. This compares to year-ago revenues of $16.52 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Butterfly Network shares have added about 19.6% since the beginning of the year versus the S&P 500's decline of -0.3%.

What's Next for Butterfly Network?

While Butterfly Network has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Butterfly Network: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.09 on $21.66 million in revenues for the coming quarter and -$0.33 on $95.3 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Senseonics Holdings (SENS), is yet to report results for the quarter ended December 2024. The results are expected to be released on March 3.

This medical technology company is expected to post quarterly loss of $0.03 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Senseonics Holdings' revenues are expected to be $8.3 million, up 3.8% from the year-ago quarter.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Butterfly Network, Inc. (BFLY) : Free Stock Analysis Report

Senseonics Holdings, Inc. (SENS) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10